Brief: CytRx Corp Says Aldoxorubicin continues to demonstrate positive clinical activity in phase 2 Glioblastoma trial
23/11/2015 14:00
Nov 23 (Reuters) - CytRx Corp CYTR.O : * Aldoxorubicin continues to demonstrate positive clinical activity in phase 2 glioblastoma trial * Says overall survival not yet reached * Says 57% of patients continue to be followed * Says CytRx plans to discuss pivotal trial design with the FDA * Aldoxorubicin was well tolerated at both dose levels, with all adverse events consistent with known doxorubicin toxicities * Source text for Eikon ID:nPn6YWhWw * Further company coverage CYTR.O ((Bengaluru Newsroom; +1 646 223 8780))
Recent news on LadRx
See all newsBrief: Ladrx Issues 2024 Update To Shareholders
Brief: LadRx Completes Non-Dilutive Financing Transaction For Up To $11 Mln With Xoma Corporation
Brief: LadRx Intends To Apply To List Stock On Nasdaq Under Symbol 'LADX'
Brief: LadRx Announces Review Of Strategic Alternatives, Provides Corporate Updates
Brief: CytRx Highlights Orphazyme's Update On Productive Meeting With FDA Regarding Arimoclomol In Niemann-Pick Disease Type C